Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for CMO/CDMO biotechnology services. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global CMO/CDMO biotechnology market from 2025 to 2032.
Key Insights:
• CMO/CDMO Biotechnology Market Size (2025E): US$74.0Billion
• Projected Market Value (2032F): US$ 168.9Billion
• Global Market Growth Rate (CAGR 2025 to 2032): 12.5%
CMO/CDMO Biotechnology Market - Report Scope:
CMO/CDMO biotechnology services encompass contract manufacturing and contract development solutions that support biopharmaceutical companies throughout the drug development and commercialization lifecycle. These organizations provide specialized capabilities in biologics manufacturing, cell and gene therapy production, biosimilar development, process optimization, analytical testing, fill-finish operations, and regulatory support. The market serves pharmaceutical companies, biotechnology firms, research institutions, and emerging drug developers seeking cost-efficient, scalable, and technologically advanced outsourcing solutions. Increasing biologics pipelines, rising complexity of advanced therapies, and growing demand for flexible manufacturing infrastructure continue to drive expansion across the global CMO/CDMO biotechnology market.
Market Growth Drivers:
The global CMO/CDMO biotechnology market is propelled by several key factors, including the rapid growth of biologics, biosimilars, monoclonal antibodies, cell therapies, and gene therapies. Pharmaceutical and biotechnology companies increasingly rely on outsourcing partners to reduce capital expenditure, accelerate time-to-market, and access specialized manufacturing expertise. Growing regulatory approvals for biologics and increasing investments in biotechnology research and development further stimulate demand for contract manufacturing services. Technological advancements in single-use bioprocessing systems, continuous manufacturing, process automation, and digital biomanufacturing platforms are enhancing production efficiency and scalability. Additionally, the expansion of biotechnology startups and emerging biopharma companies lacking internal manufacturing infrastructure continues to support robust market growth.
Market Restraints:
Despite promising growth prospects, the CMO/CDMO biotechnology market faces challenges related to stringent regulatory compliance requirements, capacity constraints, and high operational costs. Manufacturing biologics and advanced therapies requires sophisticated facilities, highly skilled personnel, and strict adherence to Good Manufacturing Practice (GMP) standards, resulting in substantial capital investments. Supply chain disruptions, raw material shortages, and workforce limitations may impact production timelines and service delivery. Furthermore, quality assurance risks, intellectual property concerns, and increasing competition among service providers can create operational complexities for both CDMOs and their clients. Managing evolving regulatory requirements across multiple global markets remains a significant challenge for industry participants.
Market Opportunities:
The CMO/CDMO biotechnology market presents substantial growth opportunities driven by advancements in personalized medicine, cell and gene therapies, and next-generation biologics. The increasing commercialization of advanced therapy medicinal products (ATMPs) is creating strong demand for specialized development and manufacturing capabilities. Expansion of integrated end-to-end service offerings, from early-stage research through commercial production, allows CDMOs to strengthen long-term customer relationships and generate recurring revenue streams. Furthermore, growing investments in domestic biomanufacturing initiatives, particularly across North America, Europe, and Asia Pacific, are expected to create new opportunities for capacity expansion and strategic partnerships. Adoption of artificial intelligence, predictive analytics, and smart manufacturing technologies is also enhancing operational efficiency and competitive differentiation across the industry.
Key Questions Answered in the Report:
• What are the primary factors driving the growth of the CMO/CDMO biotechnology market globally?
• Which service categories and therapeutic areas are accelerating outsourcing adoption across biopharmaceutical companies?
• How are technological advancements reshaping the competitive landscape of the CMO/CDMO biotechnology market?
• Who are the key players contributing to the CMO/CDMO biotechnology market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global CMO/CDMO biotechnology market?
Competitive Intelligence and Business Strategy:
Leading players in the global CMO/CDMO biotechnology market, including Lonza Group AG, Samsung Biologics Co., Ltd., and Catalent, Inc., focus on capacity expansion, advanced bioprocessing technologies, and strategic partnerships to strengthen their competitive positioning. These organizations continue investing heavily in biologics manufacturing facilities, cell and gene therapy platforms, single-use technologies, and digital manufacturing systems to meet growing client demand. Strategic acquisitions, geographic expansion initiatives, and integrated service offerings enable companies to provide comprehensive development and manufacturing solutions across the biopharmaceutical value chain. Furthermore, collaborations with biotechnology startups, pharmaceutical innovators, and academic research institutions support technology innovation and long-term business growth. Recent industry performance demonstrates continued demand for advanced contract manufacturing services, particularly across biologics and specialty therapeutics segments.
Key Companies Profiled:
• Lonza Group AG
• Samsung Biologics Co., Ltd.
• Catalent, Inc.
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific Inc.
• WuXi Biologics
• Boehringer Ingelheim BioXcellence
• AGC Biologics
• Recipharm AB
• Siegfried Holding AG
• Rentschler Biopharma SE
• KBI Biopharma, Inc.
• AbbVie Contract Manufacturing
• Charles River Laboratories International, Inc.
• Emergent BioSolutions Inc.
CMO/CDMO Biotechnology Market Research Segmentation:
The CMO/CDMO biotechnology market encompasses a broad range of development, manufacturing, and support services designed to facilitate the production and commercialization of biologics, biosimilars, and advanced therapeutic products.
By Service Type:
• Contract Development
• Process Development
• Analytical Testing
• Clinical Manufacturing
• Commercial Manufacturing
• Fill-Finish Services
• Packaging Services
• Regulatory Support Services
• Others
By Product Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell Therapies
• Gene Therapies
• Biosimilars
• Other Biologics
By Expression System:
• Mammalian Expression Systems
• Microbial Expression Systems
• Yeast Expression Systems
• Insect Cell Expression Systems
• Plant-Based Expression Systems
By End-User:
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Academic Organizations
• Emerging Biopharma Startups
• Others
By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global CMO/CDMO Biotechnology Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Product Type Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-economic Factors
2.3.1. Global Sectoral Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Tool Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
4. Price Analysis, 2024A
4.1. Key Highlights
4.2. Key Factors Impacting Deployment Costs
4.3. Pricing Analysis, By Product Type
5. Global CMO/CDMO Biotechnology Market Outlook
5.1. Key Highlights
5.1.1. Market Volume (Units) Projections
5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
5.3. Global CMO/CDMO Biotechnology Market Outlook: Service Type
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Service Type, 2019 - 2024
5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
5.3.3.1. Standalone Services
5.3.3.2. Integrated Contract Development & Manufacturing Services
5.3.3.3. Contract Manufacturing Services
5.3.4. Market Attractiveness Analysis: Service Type
5.4. Global CMO/CDMO Biotechnology Market Outlook: Product Type
5.4.1. Introduction / Key Findings
5.4.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2024
5.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
5.4.3.1. Monoclonal Antibodies
5.4.3.2. Cell & Gene Therapies (CGTs)
5.4.3.3. Advanced Therapy Medicinal Products (ATMPs)
5.4.3.4. Others
5.4.4. Market Attractiveness Analysis: Product Type
5.5. Global CMO/CDMO Biotechnology Market Outlook: Scale of Operation
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2024
5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
5.5.3.1. Small Scale/Pilot Production
5.5.3.2. Large Scale/Commercial Manufacturing
5.5.4. Market Attractiveness Analysis: Scale of Operation
6. Global CMO/CDMO Biotechnology Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2024
6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025 - 2032
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia and Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America CMO/CDMO Biotechnology Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
7.2.1. By Country
7.2.2. By Service Type
7.2.3. By Product Type
7.2.4. By Scale of Operation
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
7.3.1. U.S.
7.3.2. Canada
7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
7.4.1. Standalone Services
7.4.2. Integrated Contract Development & Manufacturing Services
7.4.3. Contract Manufacturing Services
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
7.5.1. Monoclonal Antibodies
7.5.2. Cell & Gene Therapies (CGTs)
7.5.3. Advanced Therapy Medicinal Products (ATMPs)
7.5.4. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
7.6.1. Small Scale/Pilot Production
7.6.2. Large Scale/Commercial Manufacturing
7.7. Market Attractiveness Analysis
8. Europe CMO/CDMO Biotechnology Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
8.2.1. By Country
8.2.2. By Service Type
8.2.3. By Product Type
8.2.4. Scale of Operation
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Türkiye
8.3.8. Rest of Europe
8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
8.4.1. Standalone Services
8.4.2. Integrated Contract Development & Manufacturing Services
8.4.3. Contract Manufacturing Services
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
8.5.1. Monoclonal Antibodies
8.5.2. Cell & Gene Therapies (CGTs)
8.5.3. Advanced Therapy Medicinal Products (ATMPs)
8.5.4. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
8.6.1. Small Scale/Pilot Production
8.6.2. Large Scale/Commercial Manufacturing
8.7. Market Attractiveness Analysis
9. East Asia CMO/CDMO Biotechnology Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
9.2.1. By Country
9.2.2. By Service Type
9.2.3. By Product Type
9.2.4. By Scale of Operation
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
9.4.1. Standalone Services
9.4.2. Integrated Contract Development & Manufacturing Services
9.4.3. Contract Manufacturing Services
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
9.5.1. Monoclonal Antibodies
9.5.2. Cell & Gene Therapies (CGTs)
9.5.3. Advanced Therapy Medicinal Products (ATMPs)
9.5.4. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
9.6.1. Small Scale/Pilot Production
9.6.2. Large Scale/Commercial Manufacturing
9.7. Market Attractiveness Analysis
10. South Asia & Oceania CMO/CDMO Biotechnology Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
10.2.1. By Country
10.2.2. By Service Type
10.2.3. By Product Type
10.2.4. By Scale of Operation
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
10.3.1. India
10.3.2. Southeast Asia
10.3.3. ANZ
10.3.4. Rest of South Asia & Oceania
10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
10.4.1. Standalone Services
10.4.2. Integrated Contract Development & Manufacturing Services
10.4.3. Contract Manufacturing Services
10.5. ICurrent Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
10.5.1. Monoclonal Antibodies
10.5.2. Cell & Gene Therapies (CGTs)
10.5.3. Advanced Therapy Medicinal Products (ATMPs)
10.5.4. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
10.6.1. Small Scale/Pilot Production
10.6.2. Large Scale/Commercial Manufacturing
10.7. Market Attractiveness Analysis
11. Latin America CMO/CDMO Biotechnology Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
11.2.1. By Country
11.2.2. By Service Type
11.2.3. By Product Type
11.2.4. By Scale of Operation
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
11.4.1. Standalone Services
11.4.2. Integrated Contract Development & Manufacturing Services
11.4.3. Contract Manufacturing Services
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
11.5.1. Monoclonal Antibodies
11.5.2. Cell & Gene Therapies (CGTs)
11.5.3. Advanced Therapy Medicinal Products (ATMPs)
11.5.4. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
11.6.1. Small Scale/Pilot Production
11.6.2. Large Scale/Commercial Manufacturing
11.7. Market Attractiveness Analysis
12. Middle East & Africa CMO/CDMO Biotechnology Market Outlook
12.1. Key Highlights
12.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
12.2.1. By Country
12.2.2. By Service Type
12.2.3. By Product Type
12.2.4. By Scale of Operation
12.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
12.3.1. GCC Countries
12.3.2. Egypt
12.3.3. South Africa
12.3.4. Northern Africa
12.3.5. Rest of Middle East & Africa
12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Service Type, 2025 - 2032
12.4.1. Standalone Services
12.4.2. Integrated Contract Development & Manufacturing Services
12.4.3. Contract Manufacturing Services
12.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025 - 2032
12.5.1. Monoclonal Antibodies
12.5.2. Cell & Gene Therapies (CGTs)
12.5.3. Advanced Therapy Medicinal Products (ATMPs)
12.5.4. Others
12.6. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
12.6.1. Small Scale/Pilot Production
12.6.2. Large Scale/Commercial Manufacturing
12.7. Market Attractiveness Analysis
13. Competition Landscape
13.1. Market Share Analysis, 2024
13.2. Market Structure
13.2.1. Competition Intensity Mapping By Market
13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
13.3.1. Lonza Group AG
13.3.1.1. Overview
13.3.1.2. Segments and Deployments
13.3.1.3. Key Financials
13.3.1.4. Market Developments
13.3.1.5. Market Strategy
13.3.2. Thermo Fisher Scientific Inc.
13.3.3. Samsung Biologics Co., Ltd.
13.3.4. Boehringer Ingelheim International GmbH
13.3.5. AGC Biologics, Inc.
13.3.6. WuXi Biologics
13.3.7. Patheon N.V.
13.3.8. Catalent, Inc.
13.3.9. AbbVie Inc.
13.3.10. Avid Bioservices, Inc.
13.3.11. Fujifilm Diosynth Biotechnologies
13.3.12. Rentschler Biopharma SE
13.3.13. KBI Biopharma (JSR Corporation)
13.3.14. Cytovance Biologics
13.3.15. Xpress Biologic
14. Appendix
14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations